One To Watch

Olema Oncology

Company Overview

A clinical-stage biotechnology company developing targeted oral therapies for breast cancer and other endocrine-driven tumors, with two pivotal Phase III trials underway for its lead asset palazestrant. Olema Oncology trades on Nasdaq under the ticker OLMA, operating under the legal name Olema Pharmaceuticals, Inc. Its pipeline is anchored in the estrogen receptor biology that drives the majority of metastatic breast cancer cases.

Headquarters and Global Presence

Olema is headquartered at 512 2nd Street in San Francisco, California, with additional operations in Cambridge, Massachusetts. The company's dual-coast footprint reflects its clinical and scientific reach across two of the US's primary biotech corridors.

Founding and History

Olema was founded in 2006 by Peter Kushner. It is headquartered in San Francisco, with operations in Cambridge, Massachusetts, and trades on Nasdaq under the ticker OLMA. The company has remained clinical-stage, concentrating on targeted therapies for breast cancer and other endocrine-driven tumors rather than diversifying, and its 2026 clinical trial collaboration with Novartis, struck alongside a $250 million equity private placement, is the clearest expression of that focus.

Therapy Areas and Focus

Olema's primary focus is ER-positive, HER2-negative breast cancer, the most prevalent subtype in metastatic disease and one where resistance to existing endocrine therapies remains a central clinical problem. The company's ambition extends to other endocrine-driven cancers, as evidenced by its move into metastatic castration-resistant prostate cancer via OP-3136. Both programs exploit the shared biology of nuclear receptor-driven tumor growth.

Technology Platforms and Modalities

Palazestrant is an oral complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD), designed to fully block and degrade the estrogen receptor without partial agonism, a limitation that has dogged earlier agents in this class. OP-3136 takes a distinct approach as an oral, selective inhibitor of KAT6A and KAT6B, lysine acetyltransferases that regulate gene expression programs linked to cancer cell survival and endocrine resistance. The two-asset strategy allows Olema to address estrogen receptor signaling from complementary angles, both directly and at the epigenetic level.

Key Pipeline and Programs

Palazestrant (OP-1250) is the company's most advanced asset, an oral CERAN/SERD in two simultaneous pivotal trials. OPERA-01 evaluates palazestrant as a single agent in patients with recurrent, locally advanced or metastatic ER-positive, HER2-negative breast cancer; enrollment is complete and top-line data are expected in the first quarter of 2027. OPERA-02 is a roughly 1,000-patient Phase III study assessing palazestrant in combination with Novartis's CDK4/6 inhibitor ribociclib in frontline metastatic breast cancer, with Novartis supplying ribociclib under a clinical trial collaboration and supply agreement.

OP-3136 is Olema's second clinical asset, an oral selective KAT6A/B inhibitor currently in Phase I development. It is being studied as a monotherapy in advanced solid tumors and in combination with endocrine therapy in ER-positive, HER2-negative advanced breast cancer. A Phase Ib/II collaboration with Bayer will evaluate OP-3136 alongside darolutamide (Nubeqa) in approximately 36 patients with metastatic castration-resistant prostate cancer, with enrollment expected to initiate in the fourth quarter of 2026.

Recent Developments

On 26 May 2026 Olema announced its clinical trial collaboration and supply agreement with Bayer for OP-3136 in mCRPC, the first clinical collaboration for that asset. Initial Phase I clinical data for OP-3136 were presented at the 2026 ASCO Annual Meeting on 21 May 2026, with preclinical data for both palazestrant and OP-3136 also featured at the 2026 AACR Annual Meeting. On 13 August 2026 Olema appointed Jason O'Byrne as chief financial officer, effective 11 August, bringing finance leadership with senior experience across Vir Biotechnology, Caribou Biosciences, Genentech, and Roche. The company reported second quarter 2026 financial and operating results on 10 August 2026.

Key Personnel

Jason O'Byrne serves as Chief Financial Officer, appointed effective 11 August 2026. He is a veteran biotech finance executive with prior senior roles at Vir Biotechnology, Caribou Biosciences, Audentes Therapeutics, Genentech, and Roche, and holds an MBA with distinction from NYU Stern and a degree in mechanical engineering from the University of British Columbia.

Strategic Partnerships

Olema's most consequential collaboration is with Novartis, which supplies ribociclib for the pivotal Phase III OPERA-02 trial; Olema also raised $250 million in an equity private placement alongside that announcement. The Bayer collaboration, announced in May 2026, provides darolutamide for the Phase Ib/II OP-3136 mCRPC study, with clinical data and inventions to be jointly owned while Olema retains full global commercial and marketing rights to OP-3136.

FAQ Section

Running OPERA-01 (monotherapy) and OPERA-02 (combination with ribociclib) in parallel lets Olema establish palazestrant's value both as a backbone therapy and as a CDK4/6 inhibitor partner, the two commercially dominant positions in metastatic ER-positive breast cancer. Sequential trials would have cost years against a field that is moving fast. OPERA-01 enrollment is already complete, with top-line data expected in Q1 2027.

Older selective estrogen receptor modulators retain partial agonist activity, meaning they can stimulate the receptor in some tissues, a property that limits their utility and contributes to resistance. A complete estrogen receptor antagonist blocks the receptor without any agonism while simultaneously tagging it for degradation, a combination intended to deliver deeper and more durable suppression of ER signaling. This dual mechanism is the theoretical basis for palazestrant's differentiation in a class that now includes several oral SERDs.

Where palazestrant targets the estrogen receptor directly, OP-3136 acts upstream at the epigenetic level, inhibiting KAT6A and KAT6B acetyltransferases that control gene expression programs cancer cells rely on for survival and endocrine resistance. This creates a rationale for combination with both endocrine therapy in breast cancer and androgen receptor inhibition in prostate cancer, which the Bayer collaboration with darolutamide is designed to test. The approach is early-stage but mechanistically distinct from any approved breast cancer endocrine agent.

OPERA-01 is a pivotal Phase III study evaluating palazestrant as a single agent in patients with recurrent, locally advanced or metastatic ER-positive, HER2-negative breast cancer. Olema has completed enrollment, making Q1 2027 the first major binary readout for the company. A positive result would establish palazestrant's monotherapy credentials and underpin its use as a combination backbone in OPERA-02.

Breast cancer is the primary focus, specifically the ER-positive, HER2-negative subtype that accounts for the majority of metastatic cases. The OP-3136/darolutamide collaboration in metastatic castration-resistant prostate cancer marks a deliberate expansion into a second endocrine-driven cancer, exploiting the shared nuclear receptor biology between the two diseases. The pipeline is currently narrow and focused rather than diversified, which concentrates both risk and upside on the OPERA-01 readout.

Olema is a late clinical-stage company at a pivotal inflection point. Its lead asset palazestrant is in two Phase III trials, with OPERA-01 top-line data expected in Q1 2027. OP-3136 is at Phase I, with the Bayer-partnered mCRPC study expected to begin enrollment in Q4 2026, making 2027 a year in which the company could have both a Phase III readout and early Phase Ib/II data from a second asset.

The key watchpoints for Olema over the next 12-18 months include:

OPERA-01 top-line data in Q1 2027, the single most consequential event in the company's near-term history.
OPERA-02 enrollment and interim data signals for the palazestrant-ribociclib combination in frontline metastatic breast cancer.
Initiation of the Bayer-partnered Phase Ib/II study of OP-3136 plus darolutamide in mCRPC, expected Q4 2026.
Competitive pressure from other oral SERDs already in or approaching approval, which could erode palazestrant's commercial opportunity even with positive Phase III data.
Cash runway and deployment of the $250 million equity placement to sustain two pivotal programs and early-stage OP-3136 trials concurrently.

Want to Update your Company's Profile?